tradingkey.logo

MannKind Corp

MNKD
View Detailed Chart

5.515USD

+0.125+2.32%
Market hours ETQuotes delayed by 15 min
1.69BMarket Cap
51.51P/E TTM

MannKind Corp

5.515

+0.125+2.32%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.32%

5 Days

-0.99%

1 Month

+47.86%

6 Months

+5.25%

Year to Date

-14.23%

1 Year

-15.93%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
31 / 507
Overall Ranking
120 / 4723
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
10.571
Target Price
+96.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 186.16% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 27.59M.%!(EXTRA int=2)
Fairly Valued
The company’s latest PE is 47.17, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 184.37M shares, increasing 1.19% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 18.10M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Ticker SymbolMNKD
CompanyMannKind Corp
CEODr. Michael E. Castagna, Pharm.D.
Websitehttps://mannkindcorp.com/
KeyAI